Q2 2026
Released Aug 4, 2026, before the open
10-Q filed Aug 4, 2026, 35 days after period end · 0001493152-26-035909
Q2 2026 · 10-Q
Revenue$190.10K$190.10K −69.5% vs Q2 2025+59.2% vs Q1 2026
Net Income-$2.62M-$2.62M N/M vs Q2 2025N/M vs Q1 2026
EPS Diluted-$0.32-$0.32 N/M vs Q2 2025N/M vs Q1 2026
Operating Income-$2,842,246N/M
Operating Cash Flowderived-$3,028,427N/M
Margins · derived
Operating margin-1495.1%−1109.1 pt vs Q2 2025
Net margin-1379.6%−1025.5 pt vs Q2 2025
What the release said
The release
Same quarter
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $190.10K | $622.85K | $89.57K | $0.00 |
| Net Income | -$2.62M | -$2.21M | -$3.07M | -$3.55M |
| EPS Diluted | -$0.32 | -$0.41 | -$0.56 | -$0.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR